The emergence of severe acute respiratory syndrome coronavirus type 2 (SARS-COV-2) has led to a global pandemic, and short- and long-term neurological consequences of COVID-19 remain a significant concern. With over five hundred million cases and nearly six million deaths, universal healthcare systems are being strained. The currently accepted toxicodynamic effects for SARS-CoV-2 acting in the CNS include an angiotensin-converting enzyme 2 (ACE2)-dependent neuroinflammatory pathway exploiting the olfactory system, infiltration of pro-inflammatory cytokines and prooxidants from blood circulation by crossing the blood-brain barrier, and access through infected immune cells.  Many patients infected with COVID-19 also experience long-term effects from their infection, currently referred to as “Post-COVID conditions (PCC)” or “long COVID”.  These SARS-CoV-2 patients experience severe CNS symptoms and disorders which include anosmia, anxiety, convulsions, depression, dysgeusia, myasthenia, restlessness, stroke, and vertigo. If these neurological symptoms/disorders are not prevented or treated appropriately, it will drastically increase the burden on healthcare and result in increased morbidity and mortality globally.  Hence, there is a requirement to develop novel prophylactic and therapeutic strategies to prevent or treat the neurological insults associated with COVID-19-induced oxidative stress, neuroinflammation, and other pathological insults which can lead to reversible or irreversible neuronal damage.  Relevant search terms contributing to the study objective were used across electronic platforms such as PubMed, Scopus, and Google Scholar, through June 2022.  This study will propose various novel natural bioactives that can be used to prevent and counteract COVID-19-induced neurological insults.